The WHO said in a July 26 executive summary it excluded GLP-1 weight loss medications because of “uncertain long-term clinical benefit and safety in this patient population.”.
“Data are lacking on long term effectiveness, optimal duration of treatment, maintenance of weight reduction once the therapy is stopped and effect on other clinically important outcomes,” such as hypertension or hyperglycaemia, the WHO said. “Long-term safety data are also lacking.”
In the revised list, the organization added drugs for multiple sclerosis, numerous infectious diseases, bone cancer and heart disease.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
